Skip to content

Evaluation of Different Colorectal Cancer Screening Strategies

Evaluation of Different Colorectal Cancer Screening Strategies: a Prospective Randomized Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05440565
Enrollment
20000
Registered
2022-07-01
Start date
2022-07-31
Completion date
2023-12-31
Last updated
2022-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Neoplasms

Brief summary

A large-scale randomized controlled trial was conducted to compare different colorectal neoplasms screening strategies.

Interventions

Fecal immunochemical test can concentrate the high-risk population.

DIAGNOSTIC_TESTAPCS score

APCS score can concentrate the high-risk population.

Sponsors

Shandong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 74 Years
Healthy volunteers
No

Inclusion criteria

* 50-74 years old * Informed consent is available

Exclusion criteria

* Previous colorectal cancer * Previous colorectal resection * Previous received cancer-related treatment (except non-melanoma skin cancer) * Colonoscopy, sigmoidoscopy, CT colonoscopy, and barium enema were performed within 5 years * Fecal occult blood or fecal DNA was performed within one year * Symptoms of lower digestive tract diseases requiring colonoscopy include: (1) rectal bleeding occurred more than once in the past 6 months, (2) recorded iron deficiency anemia, and (3) recorded significant weight loss within 6 months (\> 10% of baseline weight) * Suffering from other diseases that affect the benefit of screening or intolerance to colonoscopy (for example, severe pulmonary disease, end-stage renal disease, end-stage liver disease, severe heart failure or recently diagnosed cancer, except non-melanoma skin cancer)

Design outcomes

Primary

MeasureTime frameDescription
Detection rateup to 30 monthsDetection of intestinal lesions in population

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026